NO20000771D0 - Anvendelse av fankinon for behandling av Alzheimers sykdom - Google Patents

Anvendelse av fankinon for behandling av Alzheimers sykdom

Info

Publication number
NO20000771D0
NO20000771D0 NO20000771A NO20000771A NO20000771D0 NO 20000771 D0 NO20000771 D0 NO 20000771D0 NO 20000771 A NO20000771 A NO 20000771A NO 20000771 A NO20000771 A NO 20000771A NO 20000771 D0 NO20000771 D0 NO 20000771D0
Authority
NO
Norway
Prior art keywords
alzheimer
disease
treatment
fanquinone
prevention
Prior art date
Application number
NO20000771A
Other languages
English (en)
Other versions
NO20000771L (no
NO317770B1 (no
Inventor
Michel Xilinas
Panayotis Nikolas Gerolymatos
Original Assignee
P N Gerolymatos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by P N Gerolymatos Sa filed Critical P N Gerolymatos Sa
Publication of NO20000771D0 publication Critical patent/NO20000771D0/no
Publication of NO20000771L publication Critical patent/NO20000771L/no
Publication of NO317770B1 publication Critical patent/NO317770B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20000771A 1997-08-21 2000-02-16 Anvendelse av fankinon for behandling av Alzheimers sykdom NO317770B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR97100330 1997-08-21
GR97100507 1997-12-31
PCT/IB1998/001095 WO1999009981A1 (en) 1997-08-21 1998-07-17 Use of phanquinone for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
NO20000771D0 true NO20000771D0 (no) 2000-02-16
NO20000771L NO20000771L (no) 2000-04-25
NO317770B1 NO317770B1 (no) 2004-12-13

Family

ID=26316681

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000771A NO317770B1 (no) 1997-08-21 2000-02-16 Anvendelse av fankinon for behandling av Alzheimers sykdom

Country Status (25)

Country Link
US (2) US6670369B1 (no)
EP (1) EP1007040B1 (no)
JP (1) JP2001513558A (no)
CN (1) CN1145482C (no)
AT (1) ATE217191T1 (no)
AU (1) AU741782B2 (no)
BG (1) BG64300B1 (no)
BR (1) BR9814945A (no)
CA (1) CA2301706C (no)
CZ (1) CZ299739B6 (no)
DE (1) DE69805305T2 (no)
DK (1) DK1007040T3 (no)
EA (1) EA002526B1 (no)
ES (1) ES2177024T3 (no)
HK (1) HK1029937A1 (no)
HU (1) HUP0004331A3 (no)
IL (1) IL134263A (no)
IS (1) IS1910B (no)
NO (1) NO317770B1 (no)
NZ (1) NZ502565A (no)
PL (1) PL191208B1 (no)
PT (1) PT1007040E (no)
SK (1) SK284708B6 (no)
TR (1) TR200000455T2 (no)
WO (1) WO1999009981A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
PT1140090E (pt) * 1999-01-07 2005-05-31 Gerolymatos P N Sa Utilizacao de fanquinona para o tratamento ou prevencao da perda de memoria
AU2001250573A1 (en) * 2000-04-28 2001-11-12 Michel Xilinas Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
JP2004506915A (ja) 2000-08-18 2004-03-04 ザ　ゼネラル　ホスピタル　コーポレーション 白内障を阻害又は促進する物質を同定する方法及びその使用
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
ATE446685T1 (de) * 2003-03-11 2009-11-15 Kaneka Corp Öl-in-wasser-emulsion, die coenzym q10 enthält, und verfahren zu ihrer herstellung
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
AU2015254663B2 (en) * 2014-04-29 2020-04-02 Advantage Therapeutics, Inc. Treatment and prevention of Alzheimer's Disease (AD)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE1804736A1 (de) * 1967-11-02 1969-06-26 Ciba Geigy Pharmazeutisches Praeparat
IL40311A (en) 1972-09-06 1973-04-30 Pharmaplantex Ltd Pharmaceutical preparation for the treatment of gastro-intestinal troubles containing phanquone and furazolidone
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4981844A (en) * 1988-10-04 1991-01-01 University Of Cincinnati Method to improve immune response and resistance to infection following surgery by diet composition
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
AP387A (en) * 1991-09-13 1995-07-31 Siegbert Heinrich Bissbort Therapeutical uses of L-methionine and compositions thereof.
DE69227380T3 (de) 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
GB9126874D0 (en) * 1991-12-18 1992-02-19 Wellcome Found Medicaments
EP0713392A1 (en) * 1994-05-11 1996-05-29 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
CZ292411B6 (cs) 1996-08-13 2003-09-17 P. N. Gerolymatos S. A. Farmaceutický prostředek
AU748768B2 (en) 1997-03-11 2002-06-13 General Hospital Corporation, The Identification of agents for use in the treatment of Alzheimer's disease
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
PT1140090E (pt) 1999-01-07 2005-05-31 Gerolymatos P N Sa Utilizacao de fanquinona para o tratamento ou prevencao da perda de memoria
AU2001250573A1 (en) 2000-04-28 2001-11-12 Michel Xilinas Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AU2001250571A1 (en) 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol

Also Published As

Publication number Publication date
ES2177024T3 (es) 2002-12-01
CA2301706A1 (en) 1999-03-04
HUP0004331A2 (hu) 2001-05-28
EA200000242A1 (ru) 2000-08-28
JP2001513558A (ja) 2001-09-04
EP1007040B1 (en) 2002-05-08
AU8124198A (en) 1999-03-16
SK284708B6 (sk) 2005-09-08
IS5366A (is) 2000-01-28
US20050003018A1 (en) 2005-01-06
CN1145482C (zh) 2004-04-14
CZ299739B6 (cs) 2008-11-05
AU741782B2 (en) 2001-12-06
DE69805305T2 (de) 2002-12-05
WO1999009981A1 (en) 1999-03-04
SK2062000A3 (en) 2000-08-14
US6670369B1 (en) 2003-12-30
BR9814945A (pt) 2000-09-05
HK1029937A1 (en) 2001-04-20
IL134263A0 (en) 2001-04-30
EP1007040A1 (en) 2000-06-14
PL191208B1 (pl) 2006-03-31
IL134263A (en) 2006-04-10
TR200000455T2 (tr) 2000-09-21
NO20000771L (no) 2000-04-25
IS1910B (is) 2003-12-31
US7629354B2 (en) 2009-12-08
PL338673A1 (en) 2000-11-20
CN1267218A (zh) 2000-09-20
ATE217191T1 (de) 2002-05-15
BG64300B1 (bg) 2004-09-30
BG104179A (en) 2000-10-31
CZ2000611A3 (cs) 2000-08-16
DE69805305D1 (de) 2002-06-13
NZ502565A (en) 2002-03-01
PT1007040E (pt) 2002-10-31
CA2301706C (en) 2005-10-04
NO317770B1 (no) 2004-12-13
DK1007040T3 (da) 2002-08-26
HUP0004331A3 (en) 2001-09-28
EA002526B1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
FI962557A0 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
ES2188584T3 (es) Derivados heterociclicos de amina.
HUP0103654A2 (hu) Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására
NO20026199D0 (no) Forbindelser for behandling av Alzheimers sykdom
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
NO20000771L (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
BR0012921A (pt) Compostos calcilìticos
DK0703781T3 (da) Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
NO953072L (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
RS49595B (sr) Primena 2-fenil-1,2- benzizoselenazol-3(2h)-ona za izradu farmaceutskog preparata za lečenje alchajmerove bolesti

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees